The Humira industry is undergoing rapid transformation as biosimilar competition intensifies globally. This humira market size contraction is driven by patent expirations and biosimilar uptake. Our latest humira market report underscores that market revenue peaked at USD 20 Bn in 2021 and is forecasted to decline sharply under heightened pricing reforms.

The Global Humira Market size is estimated to be valued at USD 4.68 Bn in 2025 and is expected to reach USD 1.20 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of -17% from 2025 to 2032.

Declining unit sales and pricing pressures shape the humira market trends and dynamics, requiring manufacturers to pivot with innovative Humira Market Opportunities and optimize business growth through diversified portfolios.

Current Event & Its Impact on Market

I. Biosimilar Launch Surge (e.g., Amgen’s Amjevita rollout)
A. EU Entry by Amjevita – Accelerates price erosion and shrinks market revenue
B. US FDA Delay for ABP 501 – Temporarily cushions humira market share decline
A. India’s Local Production Expansion by Biocon – Increases global supply and intensifies regional competition

II. Pricing and Reimbursement Shifts (e.g., implementation of IRA pricing caps)
A. US Inflation Reduction Act Caps – Forces margin contraction and limits market growth
B. EU Health Technology Assessment Revisions – Alters reimbursement and reshapes market dynamics
A. Middle East Tender Favoring Biosimilars – Redirects purchasing and creates new market segments

Impact of Geopolitical Situation on Supply Chain

During 2024–25, US-China trade tensions led to retaliatory tariffs on single-use bioreactor components imported from Asia:
• Tariff hikes of up to 15% on critical filter membranes disrupted just-in-time inventory.
• Downtime in US filling lines extended lead times for Humira by 2–3 weeks.
• Companies faced higher input costs, eroding gross margins and highlighting market restraints.
• This supply‐chain squeeze underscored the need for diversified sourcing, a key market challenge and driver for future investments.

SWOT Analysis

Strengths
• Established global brand equity and market share leadership in autoimmune therapies.
• Robust patient support programs driving prescription retention and industry size resilience.
• Strong manufacturing network with scale benefiting market scope and segments coverage.

Weaknesses
• Steep revenue decline post-patent expiry, intensifying market restraints.
• High COGS for biologics versus biosimilars compressing profit margins.
• Complex cold‐chain logistics raising operational costs across key markets.

Opportunities
• Expansion into emerging markets with limited biosimilar penetration, unlocking new market opportunities.
• Development of subcutaneous formulations to improve patient adherence and market growth strategies.
• Strategic partnerships for antibody-drug conjugates to leverage platform expertise and diversify pipeline.

Threats
• Aggressive price competition from approved biosimilars eroding humira market share.
• Stringent reimbursement reforms under global healthcare policy shifts.
• Litigation risks around patent cliffs, challenging long-term market revenue and industry share.

Key Players

• AbbVie Inc.
• Amgen Inc.
• Biocon Ltd.
• Biogen Inc.
• Sandoz (Novartis)
• Samsung Bioepis
• copyright Inc.
• Celltrion Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries
• Fresenius Kabi AG
• Merck & Co., Inc.
• Janssen Pharmaceuticals (J&J)
• Roche Holding AG
• Sanofi S.A.
• Eli Lilly and Company

• In 2025, AbbVie expanded its single-use bioreactor capacity by 25%, mitigating supply bottlenecks and stabilizing humira market revenue in North America.
• Biocon formed a strategic manufacturing alliance in 2024 with a US CDMO, boosting annual output by 30% and capturing incremental market share in Asia-Pacific.

FAQs

1. Who are the dominant players in the Humira market?
AbbVie leads the Humira market, followed by biosimilar producers such as Amgen, Biocon, Biogen, and Sandoz competing on price.

2. What will be the size of the Humira market in the coming years?
The market size is projected to decline from USD 4.68 Bn in 2025 to USD 1.20 Bn by 2032, driven by biosimilar uptake and patent expirations.

3. Which end-user industry has the largest growth opportunity?
Hospital infusion centers remain the largest segment, but self-administration via subcutaneous delivery shows faster uptake in specialty clinics.

4. How will market development trends evolve over the next five years?
Expect intensified biosimilar competition, greater pressure on list prices, and expansion of support services to bolster patient retention.

5. What is the nature of the competitive landscape and challenges in the Humira market?
The landscape is shifting toward biosimilar dominance, with pricing reforms, reimbursement caps and manufacturing scale‐up as primary challenges.

6. What go-to-market strategies are commonly adopted in the Humira market?
Producers emphasize patient assistance programs, partnership with CDMOs, and innovative delivery formats to sustain market share and revenue.

Get More Insights on – Humira Market

Resources: -

Major Players - Humira Biosimilar Industry

About Author

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137)